Availability of addiction medications in private health plans

References 

1. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: A U.S. perspective. American Journal on Addictions. 2003;12:S53–S68
2. Center for Substance Abuse Treatment . Naltrexone and alcoholism treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1998;
3. Center for Substance Abuse Treatment . Clinical guidelines for the use of buprenorphine in the treatment of opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004;
4. Centers for Medicare and Medicaid Services . National health expenditures by type of service and source of funds, CY 1960–2004. Table 2: National health expenditures aggregate amounts and average annual percent change, by type of expenditure. Retrieved July 10, 2006, from http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage2006;
5. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment. 2004;27:153–159
   • Abstract
   • Full Text
   • Full-Text PDF (150 KB)
   • CrossRef
6. Frank RG, Conti RM, Goldman HW. Mental health policy and psychotropic drugs. Milbank Quarterly. 2005;83:271–298
7. Garis RI, Clark BE, Siracuse MV, Makoid MC. Examining the benefit of pharmacy benefit management companies. American Journal of Health-System Pharmacy. 2004;61:81–85
8. Gleason PP, Gunderson BW, Gericke KR. Are incentive-based formularies inversely associated with drug utilization in managed care?. Annals of Pharmacotherapy. 2005;39:339–345
9. Harris KM, Thomas C. Naltrexone and pharmacy benefit management. Journal of Addictive Diseases. 2004;23:11–29
   • MEDLINE
   • CrossRef
10. Hoadley J. Cost containment strategies for prescription drugs: Assessing the evidence in the literature. Menlo Park, CA: Kaiser Family Foundation; 2005;
11. Hodgkin D, Horgan CM, Garnick DW, Merrick EL, Volpe-Vartanian J. Management of psychotropic medications in private health plans. Clinical Therapeutics. 2007;29:371–380
    • Abstract
    • Full-Text PDF (789 KB)
    • CrossRef
12. Horgan, C. M., Garnick, D. W., Merrick, E. L., & Hodgkin, D. (in review) Changes in how health plans provide behavioral health services. Manuscript in preparation.
13. Huskamp HA. Managing psychotropic drug costs: Will formularies work?. Health Affairs. 2003;22:84–96
14. Kaiser Family Foundation . Employer health benefits 2005 annual survey. Retrieved August 2, 2006, from http://www.kff.org/insurance/7315/upload/7315.pdf2005;
15. Kemper P, Blumenthal D, Corrigan JM, Cunningham PJ, Felt SM, Grossman JM, et al. The design of the community tracking study: A longitudinal study of health system change and its effects on people. Inquiry. 1996;33:195–206
    • MEDLINE
16. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care. 2005;11:621–628
17. Mark TL. Are medications for alcoholism underutilized? An analysis of private-sector and Medicaid claims. Drug Benefits Trends. 2004;16:154–158
18. Mark TL, Coffey RM, McKusick D, Harwood H, King E, Bouchery E, et al. National expenditures for mental health services and substance abuse treatment 1991–2001 (no. SMA 05-3999). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005;
19. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews. 2006;25:
20. Nair KV, Valuck RJ. Impact of three-tier pharmacy benefit structures on consumer attitudes, pharmacy, medical utilization and costs: A critical review. Disease Management & Health Outcomes. 2004;12:81–92
21. National Institute of Alcohol Abuse and Alcoholism . Five year strategic plan FY07–FY11: Alcohol across the lifespan. Retrieved August 1, 2006, from http://pubs.niaaa.nih.gov/publications/StrategicPlan/NIAAASTRATEGICPLAN.htm2006;
22. National Institute of Drug Abuse . Principles of effective treatment for criminal justice populations. Rockville, MD: National Institute of Drug Abuse; 2006;
23. National Quality Forum . Evidence-based treatment practices for substance use disorders: Workshop proceedings. Washington, DC: National Quality Forum; 2005;
24. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost-sharing. Clinical Therapeutics. 2002;25:250–272
    • Abstract
    • Full-Text PDF (1416 KB)
    • CrossRef
25. Payte JT, Zweben JE, Martin J. Opioid maintenance treatment. In:  Graham AW,  Schultz TK,  Mayo-Smith MF,  Ries RK,  Wilford BB editor. Principles of addiction medicine. 3rd ed.. Chevy Chase, MD: American Society of Addiction Medicine; 2003;p. 751–766
26. Research Triangle Institute . SUDAAN user's manual: Release 8.0. Research Triangle Park, NC: Research Triangle Institute; 2002;
27. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology and Therapeutics. 2005;108:119–128
28. Substance Abuse and Mental Health Services Administration . Results from the 2004 National Survey on Drug Use and Health: Detailed tables. Retrieved August 3, 2006, from http://www.oas.samhsa.gov/NSDUH/2k4nsduh/2k4tabs/2k4TabsCover.pdf2005;
29. Substance Abuse and Mental Health Services Administration . 2004 National Survey on Drug Use and Health. [computer file]. Retrieved August 3, 2006, from http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00064.xml
30. The Medical Letter . Buprenorphine: An alternative to methadone. The Medical Letter on Drugs and Therapeutics. 2003;45:
31. Volkow ND. NIDA at 30: Committed to scientific solutions for drug addiction problems. NIDA Notes. 2004;19:Retrieved January 15, 2007, from http://www.drugabuse.gov/NIDA_notes/NNvol19N1/DirRepVol19N1.html